Total medical devices industry venture financing deals in Q3 2020 worth $2.62bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 5.8% over the previous quarter and a rise of 28.2% when compared with the last four-quarter average of $2.05bn.
The US held a 58.6% share of the global medical devices industry venture financing deal value that totalled $4.48bn in Q3 2020.
In terms of deal activity, the US recorded 155 deals during Q3 2020, marking a drop of 5.5% over the previous quarter and a drop of 14.4% over the last four-quarter average.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The US medical devices industry venture financing deals in Q3 2020: Top deals
The top five medical devices industry venture financing deals accounted for 33.2% of the overall value during Q3 2020.
The combined value of the top five medical devices venture financing deals stood at $870m, against the overall value of $2.62bn recorded for the month.
The top five medical devices industry deals of Q3 2020 tracked by GlobalData were:
1) Andreessen Horowitz, Bain Capital Life Sciences, BrightEdge Fund, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Data Collective Venture Capital, EcoR1 Capital, Farallon Capital Management, Fidelity Management & Research, GV Management Co, Janus Henderson Investors, Kaiser Permanente Ventures, Novartis Venture Fund, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Rock Springs Capital Management, Sands Capital Management, Section 32, Soleus Capital Management and T Rowe Price Associates’ $270m venture financing of Freenome
2) The $257m venture financing of Thrive Earlier Detection by Bain Capital Life Sciences, Brown Advisory, Casdin Capital, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital Management, Sands Capital Management, Section 32 and T Rowe Price Associates
3) Boston Scientific, Merck Global Health Innovation Fund, Novo Holdings, Samsung Catalyst Fund and Vivo Capital’s $137m venture financing of Preventice
4) The $121m venture financing of Mount Sinai Genomics by BlackRock, Connecticut Innovations, Decheng Capital, Deerfield ManagementLP, Moore Strategic Ventures, Oak HC/FT Partners, Section 32 and The Blackstone Group
5) Catalyst Health Ventures and Fidelity Management & Research’s venture financing of Conformal Medical for $85m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.